Credit Suisse Ag Annexon, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.11 - $4.06 $45,008 - $86,603	-21,331 Reduced 99.92%	17 $0
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $18,615 - $81,418	6,819 Added 46.93%	21,348 $58,000
Q4 2021 Feb 14, 2022	BUY	$11.49 - $22.0 $166,938 - $319,638	14,529 New	14,529 $166,000
Q2 2021 Aug 16, 2021	SELL	$17.81 - $27.48 $171,207 - $264,165	-9,613 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$22.0 - $35.01 $34,760 - $55,315	-1,580 Reduced 14.12%	9,613 $267,000
Q4 2020 Feb 12, 2021	BUY	$20.81 - $30.55 $232,926 - $341,946	11,193 New	11,193 $281,000

156

101M

3.73M

1.3M

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $335M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.